Current Report Filing (8-k)
January 22 2021 - 08:06AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act
of 1934
Date of Report (Date of earliest event reported): January 22,
2021
ATYR PHARMA, INC.
(Exact name of registrant as specified in its charter)
Delaware
|
|
001-37378
|
|
20-3435077
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
3545 John Hopkins Court, Suite #250
San Diego
|
|
|
|
92121
|
(Address of Principal Executive Offices)
|
|
|
|
(Zip Code)
|
Registrant’s telephone
number, including area code: (858) 731-8389
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligations of the registrant
under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, par value $0.001 per share
|
LIFE
|
The Nasdaq Capital Market
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 or
Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☒
Item 7.01 Regulation FD Disclosure.
aTyr Pharma, Inc. (the “Company”) is participating at the Society for Laboratory Automation
and Screening Digital International Conference and Exhibition
(SLAS) to be held virtually from January 25-27,
2021. The Company will be presenting a poster
presentation entitled, “A Mass Spectrometry Proteomics-Based Approach
to Identify Target Receptors for Novel Extracellular tRNA
Synthetase Fragments,” via a prerecorded audio recording on
the SLAS website. The press release announcing the
poster presentation is attached as Exhibit 99.1. The
poster presentation has been posted on the Company’s website and is
attached hereto as Exhibit 99.2.
The information under this Item 7.01, including Exhibits 99.1 and
99.2 hereto, is being furnished herewith and shall not be deemed
“filed” for the purposes of Section 18 of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), or otherwise subject
to the liabilities of that section, nor shall such information be
deemed incorporated by reference into any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except as
expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
ATYR PHARMA, INC.
|
|
|
|
|
|
|
|
By:
|
/s/ Jill M. Broadfoot
|
|
|
Jill M. Broadfoot
|
|
|
Chief Financial Officer
|
|
|
|
Date: January 22, 2021
|
|
|
3